In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
Did you know that your browser is out of date? To get the best experience using our website we recommend that you upgrade to a newer version. Learn more.

Unnecessary heart procedures can be avoided with non-invasive test

Imaging: Coronary Artery Disease
Computed Tomography


Munich, Germany – 25 Aug 2018: Unnecessary heart procedures can be avoided with a non-invasive test, according to late breaking research presented today at ESC Congress 2018 (1) and published in Journal of the American College of Cardiology.

Dr Bjarne Linde Norgaard, principal investigator, of Aarhus University Hospital, Denmark, said: “This study showed that a non-invasive method can be used to identify which patients with chest pain and clogged coronary arteries (coronary artery disease) can be safely treated with drugs and do not require invasive diagnostic tests.”

Chest pain is a warning sign of coronary artery disease which can cause a heart attack or death if the blockage stops blood flow to the heart. The severity of the blockage and its impact on blood flow determines whether treatment should be drugs, inserting a stent to open the artery, or surgery to replace the artery.

Patients with chest pain are initially assessed with coronary computed tomography angiography (CTA), a non-invasive scan that determines the degree of artery narrowing (stenosis), which is expressed as a percentage. An invasive technique called fractional flow reserve (FFR) then assesses whether the stenosis is obstructing blood flow (called ischaemia). FFR involves inserting a pressure wire into the artery then calculating the ratio between the maximum blood flow in the narrowed artery and the maximum blood flow in a normal artery.

A new non-invasive technique for assessing ischaemia uses anatomic information from standard coronary CTA scans and applies a mathematical algorithm simulating blood flow to calculate FFR. Several clinical trials have shown that this method, called FFRCT, accurately reflects invasively measured FFR. However, there is little information on clinical outcomes using coronary CTA followed by FFRCT to decide treatment.

This is the first study to show the clinical benefit of FFRCT in patients with moderate stenosis. The study included 3,674 patients with stable angina who had new onset chest pain between 2014 and 2016. All patients had coronary CTA to determine the degree of stenosis. A total of 2,540 patients had mild stenosis (less than 30%) and had no additional testing.

A total of 677 patients with moderate stenosis (30–70%) had FFRCT to guide further management. Of those, 410 (61%) patients had normal FFRCT (more than 0.80) and were treated with drugs alone, with no referral to invasive testing (coronary angiography).

Over the next three years, the incidence of a combined endpoint of all-cause death, myocardial infarction, hospitalisation for unstable angina, and unplanned revascularisation was similar in patients with mild stenosis on coronary CTA (2.8%) and patients with moderate stenosis on coronary CTA but normal FFRCT (3.9%).

“Patients with moderate stenosis on coronary CTA who had normal FFRCT were deemed at low risk of heart attack and received drugs alone,” said Dr Norgaard. “Our study shows that this is a safe strategy, since their prognosis was equally favourable to patients with no or mild stenosis who we know have good outcomes. The findings suggest that coronary CTA followed by FFRCT could be used as a gatekeeper to invasive diagnostic testing, and that patients with moderate stenosis and a normal FFRCT result do not need the invasive test.”

Patients with abnormal FFRCT (0.80 or less) either received medical therapy alone or were referred for invasive coronary angiography, depending on the number of affected arteries and their location. Dr Norgaard said: “These patients had more severe disease and a less favourable outcome, particularly those who received only medication. More research is needed to determine the best management strategy for these patients.”

Data for the study were obtained from the Western Denmark Cardiac Computed Tomography (WDCT) Registry, the Danish National Patient Registry, and the Civil Registration System.

ENDS

Notes to editor

SOURCES OF FUNDING: None.

DISCLOSURES: Dr Norgaard has received unrestricted institutional research grants from Siemens and HeartFlow.

References 

(1)"Clinical outcomes following a strategy of first-line coronary CT angiography with selective FFRCT to guide management of patients with suspected stable coronary artery disease” will be presented during the session Late Breaking Science in Imaging on Saturday 25 August from 13:30 to 15:00 in room Baku – Village 5.

ESC Press Office
For press enquiries, independent comment, please contact the ESC Press Office at press@escardio.org

To access congress scientific resources visit ESC Congress 365.


About the European Society of Cardiology

The European Society of Cardiology brings together health care professionals from more than 150 countries, working to advance cardiovascular medicine and help people lead longer, healthier lives.

About ESC Congress 2018

ESC Congress is the world’s largest and most influential cardiovascular event contributing to global awareness of the latest clinical trials and breakthrough discoveries. ESC Congress 2018 takes place 25 to 29 August at the Messe München in Munich, Germany. Explore the scientific programme.

 

This press release accompanies both a presentation and an ESC press conference at the ESC Congress 2018. Edited by the ESC from material supplied by the investigators themselves, this press release does not necessarily reflect the opinion of the European Society of Cardiology. The content of the press release has been approved by the presenter.